期刊文献+

亚砷酸、全反式维甲酸联合化疗治疗儿童急性早幼粒细胞白血病八例 被引量:1

原文传递
导出
摘要 目的观察亚砷酸(As2O3)、全反式维甲酸(ATRA)联合化疗治疗儿童急性早幼粒细胞白血病(APL)的疗效。方法8例APL患儿采用ATRA及柔红霉素(DNR)联合进行诱导、巩固及维持治疗,并定期检测PML—RARα融合基因。结果完全缓解(CR)率为87.5%,达CR中位时间为26d,并于巩固治疗期间采用As2O3与ATRA及蒽环类药物交替进行,并予以维持治疗,总疗程为3.5年。目前1例已停药,6例处于维持治疗阶段。7例患儿每3个月检测PML—RARα融合基因均为(-),仅1例患儿未达CR死亡。结论As2O3与ATRA联合化疗治疗儿童APL的疗效较满意。
出处 《白血病.淋巴瘤》 CAS 2009年第5期298-299,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献7

  • 1张之南.血液病诊断与疗效标准[M].北京:科学技术出版社,1998.304.
  • 2Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia : evolving therapeutic strategies. Blood, 2002, 99: 759-767.
  • 3Hu J, Fang J, Dong Y, et al. Arsenic in cancer therapy. Anticancer Drug, 2005, 16:119-127.
  • 4Giani M , Koken MH, Chelbi-Alix MK, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic resistant NB4 cells. Blood, 1998, 91: 4300-4310.
  • 5Wang G, Li W, Cui J, el al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol, 2004, 22: 63-71.
  • 6董萍,陈钰,赵维莅,刘元昉,陈瑜,沈志祥.再复发性急性早幼粒细胞白血病23例临床研究[J].中华血液学杂志,2003,24(3):157-159. 被引量:6
  • 7黎阳,赖冬波,方建培,赵红玉,黄绍良.全反式维甲酸 三氧化二砷联合化疗治疗儿童急性早幼粒白血病的疗效分析[J].中国实用儿科杂志,2007,22(6):448-451. 被引量:4

二级参考文献14

  • 1倪建华,陈国强,朱军,仲豪杰,唐伟,李秀松,熊树民,沈志祥,陈赛娟,王振义,陈竺.氧化砷对白血病细胞内 PML/PML-RARα 蛋白的影响[J].中华血液学杂志,1997,18(1):32-34. 被引量:33
  • 2Warrell RP Jr,Frankel SR,Miller WH Jr,et al.Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-transretinoic-acid)[J].N Eng J Med,1991,324:1385.
  • 3Huang W,Sun GL,Li XS,et al.Acute promyelocytic leukemia:clinical relenance of two major PML-RARa isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain to predict relapse[J].Blood,1993,82:1264.
  • 4Gregory J Jr,Feusner J.Acute promyelocytic leukaemia in children[J].Best Pract Res Clin Haematol,2003,16(3):483-494.
  • 5Fenaux P,Chevret S,Guerci A,et al.Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia[J].European APL Group.Leukemia,2000,14(8):1371-1377.
  • 6Wang G,Li W,Cui J,et al.An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid[J].Hematol Oncol,2004,22(2):63-71.
  • 7de Botton S,Coiteux V,Chevret S,et al.Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy[J].J Clin Oncol,2004,22(8):1404-1412.
  • 8Mann G,Reinhardt D,Ritter J,et al.Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children[J].Ann Hematol,2001,80(7):417-422.
  • 9Tallman MS,Andersen JW,Schiffer CA,et al.All-trans retinoic acid in acute promyelocytic leukemia:long-term outcome and prognostic factor analysis from the North American Intergroup protocol[J].Blood,2002,100(13):4298-4302.
  • 10Bapna A,Nair R,Tapan KS,et al.All-trans-retinoic acid (ATRA):pediatric acute promyelocytic leukemia[J].Pediatr Hematol Oncol,1998,15(3):243-248.

共引文献31

同被引文献13

  • 1Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood, 2010,115 : 1697-1702.
  • 2Sanz MA,Lo-Coeo F. Modem approaches to treating acute promyelocytic leukemia. J Clin Oneo1,2011,29 :495-503.
  • 3Vega-Ruiz A, Faderl S, Estrov Z, et al. Incidence of extramedullary dis- ease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol,2009 ,89 :489-496.
  • 4Ozpolat B, Akar U, Zorrilla-Calancha I, et al. Death-associated protein 5 (DAP5/p97/NATI) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-lnduced apoptosis in acute pmmyelo- cytie leukemia. Apoptosis ,2008,13:915-928.
  • 5Rego EM. De Santis GC. Differentiation syndrome in promyelocytic leuke- mia : clinical presentation, pathogenesis and treatment. Mediterr J Hematol Infect Dis,2011,3:48.
  • 6Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trloxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol, 2010,28 : 1047-1053.
  • 7Dayyani F, Kantarjian H, O' Bfien S,et al. Outcome of therapy-related a- cute promyeloeytie leukemia with or without arsenic trioxide as a compo- nent of frontline therapy. Cancer,2011,117 : 110-115.
  • 8Freitas RA, Silva dos Santos GA, Gimenes Teixeira HL, et al. Apoptosis induction by ( + ) alpha'toeopheryl succinate in the absence or presence of all-trans retinoie acid and arsenic trioxide in NB4, NB4-P(2 and pri- mary APL ceils. Leuk Res. 2009,33:958-963.
  • 9Yago K, Aono M, Shimada H. Molecular remission induced by gemtu- zumab ozogamicin in an elderly patient with relapsed acute premyelocyt- ic leukemia. Rinsho Ketsueki ,2010,51:286-290.
  • 10冯雅青,贺永春,张艳芳,张利东.全反式维甲酸联合亚砷酸诱导治疗急性早幼粒细胞白血病凝血及纤溶指标改变的初步研究[J].肿瘤研究与临床,2008,20(12):823-825. 被引量:4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部